Clarus Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Clarus Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $228.0K | Mar 16, 2015 |
| FY2014 | Dec 31, 2013 | $804.0K | Mar 16, 2015 |
| FY2013 | Dec 31, 2012 | $394.0K | Mar 4, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $250.44M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $264.32M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $286.02M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $315.25M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $265.97M | Mar 7, 2024 |
| FY2020 | Dec 31, 2020 | $75.95M | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | $64.49M | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | $30.01M | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | $53.56M | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | $61.02M | Mar 8, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.98M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $92.62M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $97.51M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $109.95M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $87.87M | Mar 7, 2024 |
| FY2020 | Dec 31, 2020 | $26.98M | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | $21.67M | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | $10.64M | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | $18.51M | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | $21.69M | Mar 8, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($46.56M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($52.29M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | ($10.15M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | ($69.78M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $26.09M | Mar 7, 2024 |
| FY2020 | Dec 31, 2020 | $7.07M | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | $1.18M | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | ($2.74M) | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | $36.0K | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | $12.39M | Mar 8, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.68M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($70.38M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | ($21.11M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | ($106.48M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | ($12.70M) | Mar 7, 2024 |
| FY2020 | Dec 31, 2020 | $5.52M | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | $1.56M | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | ($4.04M) | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | $892.0K | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | $4.18M | Mar 8, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.93M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $12.17M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $12.74M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $13.03M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $10.41M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $10.16M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $10.58M | Mar 7, 2022 |
| FY2020 | Dec 31, 2018 | $9.47M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $7.98M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $6.60M | Mar 4, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $105.17M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $111.95M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $114.60M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $120.81M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $90.66M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $71.43M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $68.68M | Mar 7, 2022 |
| FY2020 | Dec 31, 2018 | $65.15M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $56.30M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $49.94M | Mar 4, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.75M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($7.30M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $31.92M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $14.61M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | ($304.0K) | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $29.39M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $9.52M | Mar 7, 2022 |
| FY2020 | Dec 31, 2018 | $11.39M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | ($8.92M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $4.81M | Mar 4, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.16M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $6.74M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $5.72M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $8.25M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $17.38M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $5.41M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $4.12M | Mar 7, 2022 |
| FY2020 | Dec 31, 2018 | $3.37M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $2.85M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $2.57M | Mar 4, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $249.03M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $294.09M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $495.34M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $518.15M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $631.83M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $280.69M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $230.27M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $213.13M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $207.45M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $210.46M | Mar 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.64M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $61.00M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $203.22M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $226.04M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $261.66M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $76.10M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $49.07M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $46.92M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $44.47M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $49.65M | Mar 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.39M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $233.09M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $292.12M | Mar 5, 2026 |
| FY2025 | Dec 31, 2022 | $292.11M | Mar 5, 2026 |
| FY2024 | Dec 31, 2021 | $370.17M | Mar 6, 2025 |
| FY2023 | Dec 31, 2020 | $204.59M | Mar 7, 2024 |
| FY2022 | Dec 31, 2019 | $181.19M | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | $166.21M | Mar 7, 2022 |
| FY2020 | Dec 31, 2017 | $162.98M | Mar 8, 2021 |
| FY2019 | Dec 31, 2016 | $160.81M | Mar 9, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $3.80M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $39.32M | Mar 6, 2025 |
| FY2024 | Dec 31, 2022 | $36.28M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $91.38M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $26.72M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $18.09M | Mar 7, 2022 |
| FY2020 | Dec 31, 2018 | $18.09M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $17.75M | Mar 9, 2020 |
| FY2016 | Dec 31, 2014 | $29.63M | Mar 6, 2017 |
| FY2015 | Dec 31, 2013 | $30.62M | Mar 15, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($457.25M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($406.86M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($350.74M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($336.84M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($263.34M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($286.10M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($288.59M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($304.58M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($310.39M) | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | ($309.72M) | Mar 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.69M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $45.36M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $11.32M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $11.98M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $19.47M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $17.79M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $1.70M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $2.49M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $1.86M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $94.74M | Mar 12, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.89M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $119.79M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $138.99M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $141.53M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $34.62M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $22.67M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $22.15M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $20.84M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $21.90M | Mar 12, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 7, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 8, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 7, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 8, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 38.40M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 38.36M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 38.15M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 37.05M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 37.09M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 31.23M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | 29.76M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 29.75M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | 30.04M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | 30.02M | Mar 12, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.84M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $3.83M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $3.75M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $3.72M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $3.34M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $1.52M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $2.99M | Mar 7, 2022 |
| FY2020 | Dec 31, 2018 | $1.49M | Mar 8, 2021 |